Clinical trials: Gastrointestinal Reflux
Laryngopharyngeal Reflux
Predictive Value of Subjective and Objective Measurement Tools for Extraesophageal Reflux
Acid reflux can cause many symptoms in the throat, including discomfort or pain, and difficulty with breathing and voice problems.
- Trial name
- NCT01829074
- Volunteers
- 150 people
- Sponsor
- Respiratory Technology Corporation
Gastroesophageal Reflux, Heartburn
HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease
Determine if different levels of acid-suppression with esomeprazole for 6 months on chosen histological markers of esophageal epithelial acid-related disease in patients with upper GI symptoms.
- Conditions
- Gastroesophageal Reflux, Heartburn, Dyspepsia
- Trial name
- NCT00243724
- Testing
- Esomeprazole
- Where
- 10 sites in Canada
- Volunteers
- 350 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux
The purpose of this study is to assess the safety and efficacy of lansoprazole microgranules oral suspension, once daily (QD), in infants with gastroesophageal reflux symptoms during a 4-week treatment period.
- Trial name
- NCT00324974
- Testing
- Lansoprazole microgranules suspension
- Where
- 17 sites in United States, Poland
- Volunteers
- 162 people
- Sponsor
- Takeda
Esophagitis, Reflux
Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis
The purpose of this study was to compare the pharmacodynamics of intravenous (IV) lansoprazole to oral lansoprazole capsules, once daily (QD), in participants with erosive esophagitis.
- Trial name
- NCT00175045
- Testing
- Lansoprazole
- Volunteers
- 68 people
- Sponsor
- Takeda
GERD (Gastroesophageal Reflux Disease)
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
The goal of this clinical trial is to find out how well linaprazan glurate can heal erosive esophagitis (EE) caused by gastroesophageal reflux disease (GERD), compared to lansoprazole, a commonly used medication.
- Trial name
- NCT07037875
- Testing
- Linaprazan glurate 50 mg Twice Daily (BID), Linaprazan Glurate 50 mg Once Daily (QD), Lansoprazole 30 mg Once Daily (QD)
- Where
- 87 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 523 people
- Sponsor
- Cinclus Pharma Holding AB
Gastroesophageal Reflux Disease
Efficacy of Pantoprazole 20/40 mg Once Daily (od) in Patients Older Than 12 Years Who Have Gastrointestinal Symptoms of Reflux Disease
The aim of this study was to evaluate the effect of 14 days treatment with Pantoprazole 40 mg and 20 mg on gastroesophageal reflux disease (GERD) related symptoms in a large patient population.
- Trial name
- PARADE (NCT00829738)
- Testing
- Pantoprazole
- Where
- 717 sites in Germany
- Volunteers
- 4,188 people
- Sponsor
- Nycomed
Gastroesophageal Reflux Disease
A Study to Compare PK, PD and Safety of the AD-214 and AD-2141
A study to compare safety, pharmacokinetics and pharmacodynamics of AD-214 to AD-2141 in healthy volunteers.
- Trial name
- NCT05062876
- Testing
- AD-214, AD-2141
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Healthy Volunteers
A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants
The primary objective of this study is to assess the bioavailability (BA) of a single oral dose of vonoprazan 20 mg sprinkle capsule, either sprinkled on pudding or on applesauce, relative to a vonoprazan 20 mg tablet in healthy…
- Trial name
- NCT05366738
- Testing
- Vonoprazan
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Phathom Pharmaceuticals, Inc.
Gastroesophageal Reflux Disease, Hiatal Hernia
Transoral Incisionless Fundoplication (TIF) Registry Study for Treatment of Gastroesophageal Reflux Disease (GERD)
The study objective is to evaluate the safety and efficacy of TIF among a broad range of GERD patients treated in routine clinical practice at multiple centers across the United States.
- Trial name
- NCT01118585
- Testing
- TIF Procedure
- Where
- 14 sites in United States
- Volunteers
- 278 people
- Sponsor
- EndoGastric Solutions
Non-erosive Reflux Disease(NERD)
Clinical Trial to Evaluate the Efficacy and Safety of EsoDuo Tab. 20/800mg
To Evaluate the Efficacy and Safety of EsoDuo Tab. 20/800mg
- Trial name
- NCT03928470
- Testing
- EsoDuo Tab. 20/800mg
- Where
- 38 sites in South Korea
- Volunteers
- 379 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Gastroesophageal Reflux Disease
Maintenance Intermittent Therapy for Symptomatic GERD Patients
The purpose of this study to determine the efficacy of 20 mg of rabeprazole given as a maintenance intermittent therapy following acute treatment for Symptomatic Gastroesophageal Reflux Disease (s-GERD).
- Trial name
- NCT00165841
- Testing
- Rabeprazole 20 mg
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Eisai Inc.
Gastroesophageal Reflux
Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to provide additional information on safety and tolerability after multiple does of pantoprazole. Only patients who successfully completed the 3001B3-331 study (NCT00362609) or 3001B3-333 study…
- Trial name
- NCT00868296
- Testing
- pantoprazole
- Where
- 71 sites in United States, Australia and 9 more
- Volunteers
- 58 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Refractory Reflux Esophagitis
Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of…
- Trial name
- NCT01669811
- Testing
- Esomeprazole (D961H) twice daily, Esomeprazole (D961H) once daily
- Where
- 63 sites in Japan
- Volunteers
- 1,398 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux
Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)
Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD occurs when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the…
- Trial name
- NCT00163306
- Testing
- Pantoprazole
- Where
- 79 sites in Austria, Germany and 2 more
- Volunteers
- 1,200 people
- Sponsor
- Takeda
Gastro-esophageal Reflux
Safety & Initial Efficacy of the LunGuard PFT Sys. on Enteral-Fed, Sedated and Mechanically Ventilated Patients Peristaltic Feeding Tube
This study is designated to test the safety and initial efficacy of the LunGuard's PFT device for reduction of GER. Enterally-Fed, Sedated and Mechanically Ventilated Critically Ill Patients in the ICU will have the PFT…
- Trial name
- PFT (NCT02609620)
- Testing
- Peristaltic Feeding Tube, ConvaTec Levin Duodenal Tube
- Volunteers
- 20 people
- Sponsor
- LunGuard Ltd.
GERD
A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease
The purpose of the study is to evaluate the efficacy and safety of arbaclofen placarbil (XP19986) compared to placebo in patients with gastroesophageal reflux disease.
- Trial name
- NCT00838396
- Testing
- XP19986 CR
- Where
- 3 sites in United States
- Volunteers
- 58 people
- Sponsor
- Indivior Inc.
Gastroesophageal Reflux Disease
Symptom Adapted Therapy in GERD Patients
The purpose of the study is to determine whether a maintenance treatment over 12 weeks with esomeprazole 20 mg daily will sufficiently give control over GERD symptoms and how it compares either with an on-demand therapy with…
- Trial name
- SYMPATHY (NCT00343161)
- Testing
- esomeprazole, Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)
- Where
- 96 sites in Germany
- Volunteers
- 441 people
- Sponsor
- AstraZeneca
Erosive Esophagitis
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
The aim of the study is to compare the safety and efficacy of two doses of Nexium in maintaining healing of erosive esophagitis in patients 1 to 11 years of age.
- Trial name
- EE (NCT05267613)
- Testing
- Nexium 20mg, Nexium 10mg
- Where
- 41 sites in United States, Argentina and 8 more
- Volunteers
- 53 people
- Sponsor
- AstraZeneca
Non-erosive Reflux Disease
Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD)
Randomized, double-blind, active-controlled, multi-center phase 2 clinical trial to investigate the safety, tolerability and efficacy of YH1885L in patients with non-erosive reflux disease(NERD)
- Trial name
- NCT01750437
- Testing
- YH1885L(Revaprazan), Esomeprazole 20mg
- Where
- 10 sites in South Korea
- Volunteers
- 149 people
- Sponsor
- Yuhan Corporation
GERD, Cardiac Event
Cardiac Safety of Lansoprazole and Domperidon Combination
The aim of current study is to compare safety and efficacy of lansoprazole/domperidone 30/30 mg sustained release capsules (brand name: Duolans) and lansoprazole 30 mg micropellet capsules (brand name: Lasotab) in GERD patients…
- Conditions
- GERD, Cardiac Event, Safety Issues
- Trial name
- NCT03355170
- Testing
- Lansoprazole/Domperidone, Lansoprazole
- Where
- 16 sites in Turkey (Türkiye)
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş